Investigating the Opportunity for a New Oral Chemical Entity, Gildeuretinol, for the treatment of Geographic Atrophy Secondary to AMD
Time: 2:00 pm
day: Conference Day Two
Details:
- Summarizing the gildeuretinol program and Alkeus’ efforts to understand mechanisms of disease
- Discussing results of SAGA, a 2-year, randomized, double-masked, placebo-controlled study
- Sharing next steps in the development pathway for gildeuretinol